ĐÁNH GIÁ KẾT QUẢ HÓA TRỊ BỔ TRỢ DOCETAXEL VÀ CYCLOPHOSPHAMID TRÊN BỆNH NHÂN UNG THƯ VÚ GIAI ĐOẠN I, II

Abstract

Objectives: Evaluate the treatment results of adjuvant chemotherapy regimens of Docetaxel plus Cyclophosphamide after surgery for breast cancer stage I – II and toxicity of this regiments in this group. Patients and methods: Retrospective description with longitudinal follow-up on 62 patients diagnosed with stage I, II breast cancer underwent total mastectomy or conservative surgery with adjuvant chemotherapy regimens of Docetaxel plus Cyclophosphamide at National Cancer Hospital from September 2015 to December 2020. Results: The mean age was 50±9,3. 56,4% of patients with a history of cardiovascular disease. Invasive carcinoma of no special type (NST) accounted for the highest rate 87,1% and 54,8% was in grade 2. Toxicity: The most common leukopenia and granulocytosis toxicity accounted for 23% and 29%. Hair loss is the most common side effect, accounting for 100%, anorexia is quite common, accounting for 56,5%. Peripheral edema occurred in 14,5%. Disease-free survival after 5 years is 90,0%, overall survival rate after 5 years is 93,2%. Conclusion: Docetaxel plus Cyclophosphamide adjuvant chemotherapy regimens in patients with stage I, II breast cancer has a high disease control rate and is well tolerated by patients. Therefore, it can be widely applied in clinical practice.